Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. (15th July 2022)

• Record Type: Journal Article
• Authors: Horton, Ari E; Martin, Andrew C; Srinivasan, Shubha; Justo, Robert N; Poplawski, Nicola K; Sullivan, David; Brett, Tom; Chow, Clara K; Nicholls, Stephen J; Pang, Jing; Watts, Gerald F
• Is Part Of: Journal of paediatrics and child health. Volume 58:Number 8(2022)
• Page Start: 1297
• Page End: 1312
• Publication Date: 2022-07-15
• Subjects: cardiovascular disease -- familial hypercholesterolaemia -- genetic testing -- inherited cardiac disease -- paediatrics; Children -- Health and hygiene -- Periodicals; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/jpc.16096
• Languages: English
• ISSNs: 1034-4810

Abstract

Abstract : Familial hypercholesterolaemia (FH) is a highly penetrant monogenic disorder present from birth that markedly elevates plasma low‐density lipoprotein (LDL)‐cholesterol (LDL‐C) concentration and, if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). At a prevalence of 1:250 individuals, with over 90% undiagnosed, recent estimates suggest that there are approximately 22 000 children and adolescents with FH in Australia and New Zealand. However, the overwhelming majority remain undetected and inadequately treated until adulthood or after their first cardiac event. The guidance in this paper aims to increase awareness about paediatric FH and provide practical advice for the diagnosis and management of FH in children and adolescents. Recommendations are given on the detection, diagnosis, assessment and management of FH in children and adolescents. Recommendations are also made on genetic testing, including counselling and the potential for universal screening programmes. Practical guidance on management includes treatment of non‐cholesterol risk factors, and safe and appropriate use of LDL‐C lowering therapies, including statins, ezetimibe, PCSK9 inhibitors and lipoprotein apheresis. Models of care for FH need to be adapted to local and regional health care needs and available resources. Targeting the detection of FH as a priority in children and young adults has the potential to alter the natural history of atherosclerotic cardiovascular disease and recognise the promise of early detection for improving long‐term health outcomes. A comprehensive implementation strategy, informed by further research, including assessments of cost–benefit, will be required to ensure that this new guidance benefits all families with or at risk of FH.